MFOLFOX is named as a drug or biological intervention in 3 clinical trials in our China and USA trial registers, 2 of which are recruiting. Lead sponsors include Innovent Biologics (Suzhou) Co. Ltd. (1), Yanqiao Zhang (1) and InnoPharmax Inc. (1). Registered phases: Phase 1, Phase 2 and Phase 2/3. Conditions studied include Locally Advanced Unresectable or Metastatic Solid Tumors; Colorectal Cancer; Biliary Tract Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05065957 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer |
Phase 2/3 | Recruiting |
| NCT05458219 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Locally Advanced Unresectable or Metastatic Solid Tumors |
Phase 1 | Recruiting |
| NCT07229846 | A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation (ClinicalTrials.gov ↗) Colorectal Cancer |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Locally Advanced Unresectable or Metastatic Solid Tumors | 1 |
| Colorectal Cancer | 1 |
| Biliary Tract Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | 1 |
| Yanqiao Zhang | 1 |
| InnoPharmax Inc. | 1 |
| Register | MFOLFOX trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MFOLFOX works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MFOLFOX (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.